A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza

Trial Profile

A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Peramivir (Primary) ; Oseltamivir
  • Indications Influenza virus infections
  • Focus Adverse reactions; Registrational
  • Sponsors BioCryst Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2017 Results (n=108) presented at the IDWeek 2017
    • 08 Oct 2017 122 subjects were enrolled up to a data cutoff of March 31, 2017.
    • 08 Oct 2017 Interim results (n=108) presented at the IDWeek 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top